Star Therapeutics to Present Phase 1/2 VGA039 Data at ISTH 2026
SOUTH SAN FRANCISCO, Calif., June 26, 2026 Star Therapeutics announced it will present complete safety and efficacy data from...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., June 26, 2026 Star Therapeutics announced it will present complete safety and efficacy data from...
WILMINGTON, Delaware, USA – June 8, 2026 Incyte Corporation has announced a definitive agreement to acquire Vega Therapeutics, a...
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2025 — Star Therapeutics announced it has closed an oversubscribed $125 million Series...
